Skip to main content
Journal of Cellular and Molecular Medicine logoLink to Journal of Cellular and Molecular Medicine
letter
. 2020 Aug 11;24(18):11030–11033. doi: 10.1111/jcmm.15722

Superparamagnetic iron oxide nanoparticles promote ferroptosis of ischemic cardiomyocytes

Hao Zheng 1, Jieyun You 1, Xiaobo Yao 1, Qizheng Lu 1, Wei Guo 1, Yunli Shen 1,
PMCID: PMC7521151  PMID: 32780538

1. INTRODUCTION AND BACKGROUND

Superparamagnetic iron oxide nanoparticles (SPION) have been widely used in the diagnosis and treatment for cardiovascular diseases. 1 , 2 , 3 , 4 , 5 , 6 Correspondingly, the myocardial tissue safety of SPION is becoming a bottleneck to seriously restrict its clinical translation. In recent years, in vitro and in vivo experiments have confirmed that SPION‐induced oxidative stress of normal myocardium in mice, leading to myocardial cell injury, apoptosis or necrosis. 7 , 8 , 9 More alarmingly, SPION applied to ischemic myocardium could accumulate in the target sites for a long time with high concentration, 5 , 6 , 10 thereby probably further aggravating oxidative stress injury and cardiomyocytes death. 11 , 12

So far, however, the specific molecular mechanism of cardiotoxicity of SPION remains unclear. Previous studies have reported that SPION‐induced apoptosis of murine macrophage (J774) cells 13 and necrosis of human endothelial cells. 14 SPION can selectively induce autophagy‐mediated cell death of human cancer cells (A549). 15 After SPION pre‐treatment, H9C2 cardiomyocytes were exposed to acrolein or H2O2, leading to reactive oxygen species (ROS) dependent cell necrosis. 7 Our in vitro experiment showed that SPION significantly increased oxidative stress damage to overactivate autophagy and endoplasmic reticulum stress, eventually resulting in cardiomyocyte apoptosis. 12 Furthermore, SPION could elicit IL‐1βrelease and pyroptosis in macrophages, especially with the octapod and plate morphology. 16 Notably, it has been recently reported that sorafenib or cisplatin assembled into nano‐devices containing SPION, which are phagocytized by tumour cells and degraded into free divalent iron to accelerate Fenton reaction, leading to the lipid peroxidation burst to promote ferroptosis of tumour cells. 17 , 18

Taken together, SPION can induce apoptosis, necrosis, autophagy, pyroptosis or ferroptosis in vitro and in vivo studies. The discrepancy may be attributed to distinct cell types and experiments design. It has already been well documented that the toxicity of SPION is mainly due to its degradation and release of free iron to catalyse Fenton reaction, leading to oxidative stress by a large number of ROS generation. 19 , 20 Then, what is the downstream molecular mechanism of SPION mediated cardiotoxicity?

Ferroptosis is a novel form of regulated cell death characterized by the iron‐dependent accumulation of lipid peroxides to lethal levels, which is morphologically, biochemically, and genetically distinct from apoptosis, necroptosis and autophagy. 21 Recent studies found that ferroptosis is not only an important pathological mechanism in the case of circulating iron overload of hemochromatosis, 22 but also a key molecular mechanism of cellular iron overload in doxorubicin (DOX) induced cardiomyopathy. 23 DOX induced mitochondria iron overload by down‐regulating ABCB8, 24 a mitochondrial protein that facilitates iron export, to elicit lipid peroxidation and mitochondria dysfunction, eventually causing cardiomyocytes ferroptosis. 23 Mice that were subjected to 30 minutes of myocardial ischemia followed by 24 hours of reperfusion had significantly higher levels of cardiac non‐heme iron, cardiac ferritin H, ferritin L and Ptgs2 mRNA. Both ferroptosis inhibitor Ferrostatin‐1 (Fer‐1) and iron chelator Dexrazoxane (DXZ) pre‐treatment significantly reduced I/R‐induced cardiac remodelling and fibrosis, indicating that ischemia‐reperfusion could also induce cardiomyocytes iron overload to cause ferroptosis and subsequent left ventricular remodelling. 23 Myocardial haemorrhage is a frequent complication after successful myocardial reperfusion, 25 , 26 which is associated with residual myocardial iron in post‐myocardial infarction (MI) patients received reperfusion therapy. 27 It is reasonable to infer that this iron accumulation has a potential to generate excessive ROS and trigger pathological events such as ferroptosis. A previous study also confirmed that ferroptosis is a significant type of cell death in cardiomyocytes; moreover, mechanistic target of rapamycin (mTOR) was found to play an important role in protecting cardiomyocytes against excess iron and ferroptosis by regulating ROS production. 28 In addition, glutathione peroxidase 4 (GPX4), which protects cells from ferroptosis, was down‐regulated in the early and middle stages of MI mouse model, suggesting that ferroptosis during MI was in part due to a reduction in GPX4 protein. 29

Even though signalling pathways of ferroptosis in cardiovascular diseases is not yet well characterized, it has been confirmed that ischemia‐reperfusion (I/R) could induce mitochondrial iron overload in cardiomyocytes rather than the increase of iron content in cytoplasm. 30 In this study, mice treated with 2,2′‐bipyridyl (BPD), which has high membrane permeability and thus is able to access mitochondria, had demonstrated protective effects on I/R myocardium, while deferoxamine (DFO) failed to protect mice against I/R damage due to poor penetrance into mitochondria. Notably, overexpression of ABCB8 in cardiomyocytes in mice reduces mitochondrial iron and protects against I/R damage, 30 suggesting that ABCB8 might play an important role in maintaining iron homeostasis in myocardial mitochondria and regulating ferroptosis after I/R injury. Thus, it is not difficult to speculate that SPION could aggravate mitochondrial iron load in I/R myocardium. SPION applied in ischemic myocardium could be directly degraded by cardiomyocytes, 12 leading to severe mitochondrial iron overload.

We detected prominently mitochondrial lipid peroxidation (malondialdehyde, MDA), mitochondrial membrane potential (MMP) loss and ATP depletion at 24 hours and 4 weeks after SPION injected into the peri‐infarcted zones of myocardial ischemia‐reperfusion rats compared with the control group (all P < .01). We found that iron content of mitochondria was significantly higher than that in the control group (P < .001), and the distorted mitochondria were observed by transmission electron microscopy in the SPION group, suggesting that SPION have the potential to destroy mitochondrial structure and function by inducing mitochondria iron overload (data not published). Mitochondria are the major site of iron metabolism and ROS production, thereby cardiomyocytes iron accumulation is especially prone to induce mitochondria iron overload to trigger mitochondrial oxidative damage. Based on the above results, we speculate that SPION might further promote ferroptosis to aggravate left ventricular remodelling and cardiac deterioration by inducing severe mitochondria iron overload to promote lipid peroxidation burst.

2. HYPOTHESIS

To summarize, we speculate that SPION applied to ischemic myocardium could exacerbate cardiomyocytes ferroptosis to worsen left ventricular negative remodelling through inducing mitochondria iron overload to catalyse sustained Fenton reaction, eliciting lipid peroxidation burst(as shown in Figure 1). This hypothesis needs to be verified by animal experiments. Firstly, the mitochondrial iron metabolism, lipid peroxidation, morphology and function of mitochondria and ferroptosis should be carefully detected after SPION injected into the peri‐infarcted zones of myocardial ischemia‐reperfusion rats. Secondly, the rat models of myocardial ischemia‐reperfusion were randomly divided into different groups to, respectively, treated with apoptosis inhibitor, necrosis inhibitor, autophagy inhibitor and ferroptosis inhibitor, in order to verify whether ferroptosis play a pivotal role in cardiomyocytes death induced by SPION. Thirdly, SPION were injected into the myocardium of I/R mice model, in which Mlkl −/− or Fadd −/− Mlkl −/− mice were employed to respectively block the pathways of myocardial cell necroptosis or apoptosis, in order to further illustrate whether ferroptosis is the main pathway of SPION‐induced cardiomyocytes death. Fourthly, developing SPION modified by mitochondrial iron chelator or mitochondrial‐targeted antioxidant, the effects of two strategies to improve the myocardial safety of SPION should be comprehensively investigated in vitro and in vivo experiments, potentially promoting the clinical transformation of SPION in cardiovascular field.

FIGURE 1.

FIGURE 1

SPION were internalized into cardiomyocytes and further degraded into free ferrous iron in lysosomes. The free ferrous iron entered into mitochondria, resulting in lipid peroxidation of mitochondria to trigger ferroptosis in cardiomyocytes by a large amount of ROS produced via Fenton reaction

3. IMPLICATION

The cardiotoxicity of SPION limits its diagnostic or therapeutic application in the cardiovascular field. It is helpful to promote the clinical transformation of SPION in cardiovascular field through rescuing the key target of SPION‐induced cardiomyocyte ferroptosis to improve the myocardial tissue safety. If our hypothesis is true, given that SPION mainly induce mitochondria iron overload of ischemic cardiomyocytes to catalyse lipid peroxidation and exacerbate ferroptosis, and then it is expected to significantly inhibit ferroptosis induced negative remodelling of ischemic myocardium by mitochondrial iron chelator or mitochondrial‐targeted antioxidant peptide modifying SPION to effectively protect mitochondria.

CONFLICT OF INTEREST

The authors confirm that there are no conflicts of interest.

ACKNOWLEDGEMENTS

The authors gratefully acknowledge the financial support from the National Natural Science Foundation of China, Grant/Award Number: 81500201; the Natural Science Foundation of Jiangxi Province of China (20192BAB205006); Top‐level Clinical Discipline Project of Shanghai Pudong District Grant/Award Number: PWYgf2018‐02; the National Key Research and Development Program of China (2016YFC1301200).

Zheng H, You J, Yao X, et al. Superparamagnetic iron oxide nanoparticles promote ferroptosis of ischemic cardiomyocytes. J Cell Mol Med. 2020;24:11030–11033. 10.1111/jcmm.15722

Hao Zheng and Jieyun You contributed equally to this work.

REFERENCES

  • 1. Magro M, Baratella D, Bonaiuto E, de A. Roger J, Vianello F. New perspectives on biomedical applications of iron oxide nanoparticles. Curr Med Chem. 2018;25:540‐555. [DOI] [PubMed] [Google Scholar]
  • 2. Yilmaz A. Visualising inflammation after myocardial infarction with the use of iron oxide nanoparticles. Heart. 2017;103:1479‐1480. [DOI] [PubMed] [Google Scholar]
  • 3. Alam SR, Stirrat C, Richards J, et al. Vascular and plaque imaging with ultrasmall superparamagnetic particles of iron oxide. J Cardiovasc Magn Reson. 2015;17:83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Yang H, Wei L, Liu C, et al. Engineering human ventricular heart tissue based on macroporous iron oxide scaffolds. Acta Biomater. 2019;88:540‐553. [DOI] [PubMed] [Google Scholar]
  • 5. Shen Y, Liu X, Huang Z, et al. Comparison of magnetic intensities for mesenchymal stem cell targeting therapy on ischemic myocardial repair: high magnetic intensity improves cell retention but has no additional functional benefit. Cell Transplant. 2015;24:1981‐1997. [DOI] [PubMed] [Google Scholar]
  • 6. Huang Z, Shen Y, Pei N, et al. The effect of nonuniform magnetic targeting of intracoronary‐delivering mesenchymal stem cells on coronary embolisation. Biomaterials. 2013;34:9905‐9916. [DOI] [PubMed] [Google Scholar]
  • 7. Luo C, Li Y, Yang L, Wang X, Long J, Liu J. Superparamagnetic iron oxide nanoparticles exacerbate the risks of reactive oxygen species‐mediated external stresses. Arch Toxicol. 2015;89:357‐369. [DOI] [PubMed] [Google Scholar]
  • 8. Nemmar A, Beegam S, Yuvaraju P, et al. Ultrasmall superparamagnetic iron oxide nanoparticles acutely promote thrombosis and cardiac oxidative stress and DNA damage in mice. Part Fibre Toxicol. 2016;13:22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Manickam V, Periyasamy M, Dhakshinamoorthy V, Panneerselvam L, Perumal E. Recurrent exposure to ferric oxide nanoparticles alters myocardial oxidative stress, apoptosis and necrotic markers in male mice. Chem Biol Interact. 2017;278:54‐64. [DOI] [PubMed] [Google Scholar]
  • 10. Huang Z, Li C, Yang S, et al. Magnetic resonance hypointensive signal primarily originates from extracellular iron particles in the long‐term tracking of mesenchymal stem cells transplanted in the infarcted myocardium. Int J Nanomedicine. 2015;10:1679‐1690.25767388 [Google Scholar]
  • 11. Shen Y, Huang Z, Liu X, et al. Iron‐induced myocardial injury: an alarming side effect of superparamagnetic iron oxide nanoparticles. J Cell Mol Med. 2015;19:2032‐2035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Shen Y, Gong S, Li J, et al. Co‐loading antioxidant N‐acetylcysteine attenuates cytotoxicity of iron oxide nanoparticles in hypoxia/reoxygenation cardiomyocytes. Int J Nanomedicine. 2019;14:6103‐6115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Naqvi S, Samim M,Samim M, et al. Concentration‐dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress. Int J Nanomedicine. 2010;5:983‐989. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 14. Hanini A, Schmitt A, Kacem K, Chau F, Ammar S, Gavard J. Evaluation of iron oxide nanoparticle biocompatibility. Int J Nanomedicine. 2011;6:787‐794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Khan MI, Mohammad A, Patil G, Naqvi SA, Chauhan LK, Ahmad I. Induction of ROS, mitochondrial damage and autophagy in lung epithelial cancer cells by iron oxide nanoparticles. Biomaterials. 2012;33:1477‐1488. [DOI] [PubMed] [Google Scholar]
  • 16. Liu L, Sha R, Yang L, et al. Impact of morphology on iron oxide nanoparticles‐induced inflammasome activation in macrophages. ACS Appl Mater Interfaces. 2018;10:41197‐41206. [DOI] [PubMed] [Google Scholar]
  • 17. Sang M, Luo R, Bai Y, et al. Mitochondrial membrane anchored photosensitive nano‐device for lipid hydroperoxides burst and inducing ferroptosis to surmount therapy‐resistant cancer. Theranostics. 2019;9:6209‐6223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Shen Z, Liu T, Li Y, et al. Fenton‐reaction‐acceleratable magnetic nanoparticles for ferroptosis therapy of orthotopic brain tumors. ACS Nano. 2018;12:11355‐11365. [DOI] [PubMed] [Google Scholar]
  • 19. Gordan R, Wongjaikam S, Gwathmey JK, Chattipakorn N, Chattipakorn SC, Xie LH. Involvement of cytosolic and mitochondrial iron in iron overload cardiomyopathy: an update. Heart Fail Rev. 2018;23:801‐816. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Kobayashi M, Suhara T, Baba Y, Kawasaki NK, Higa JK, Matsui T. Pathological roles of iron in cardiovascular disease. Curr Drug Targets. 2018;19:1068‐1076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron‐dependent form of nonapoptotic cell death. Cell. 2012;149:1060‐1072. 10.1016/j.cell.2012.03.042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Wang H, An P, Xie E, et al. Characterization of ferroptosis in murine models of hemochromatosis. Hepatology. 2017;66:449‐465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Fang X, Wang H, Han D, et al. Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci U S A. 2019;116:2672‐2680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Ichikawa Y, Ghanefar M, Bayeva M, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest. 2014;124:617‐630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Ganame J, Messalli G, Dymarkowski S, et al. Impact of myocardial haemorrhage on left ventricular function and remodelling in patients with reperfused acute myocardial infarction. Eur Heart J. 2009;30:1440‐1449. [DOI] [PubMed] [Google Scholar]
  • 26. Carrick D, Haig C, Ahmed N, et al. Myocardial hemorrhage after acute reperfused ST‐segment‐elevation myocardial infarction: relation to microvascular obstruction and prognostic significance. Circ Cardiovasc Imaging. 2016;9:e004148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Bulluck H, Rosmini S, Abdel‐Gadir A, et al. Residual myocardial iron following intramyocardial hemorrhage during the convalescent phase of reperfused ST‐segment‐elevation myocardial infarction and adverse left ventricular remodeling. Circ Cardiovasc Imaging. 2016;9, 004940. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Baba Y, Higa JK, Shimada BK, et al. Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes. Am J Physiol Heart Circ Physiol. 2018;314:H659‐H668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Park T‐J, Park JH, Lee GS, et al. Quantitative proteomic analyses reveal that GPX4 downregulation during myocardial infarction contributes to ferroptosis in cardiomyocytes. Cell Death Dis. 2019;10:835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Chang H‐C, Wu R, Shang M, et al. Reduction in mitochondrial iron alleviates cardiac damage during injury. EMBO Mol Med. 2016;8:247‐267. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Cellular and Molecular Medicine are provided here courtesy of Blackwell Publishing

RESOURCES